Haematological malignancies
Explore our latest news, features and educational resources in this specialist area.
SMC accepts acalabrutinib for chronic lymphocytic leukaemia (restricted use)
Acalabrutinib is recommended as monotherapy under two indications.
SMC accepts treatment for relapsed and refractory multiple myeloma (restricted use)
Isatuximab accepted in combination with pomalidomide and dexamethasone for patients receiving fourth-line therapy.
#VisualAbstract Rituximab plus high-dose chemotherapy (MegaCHOEP) show similar long-term efficacy to conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma
#VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy
#VisualAbstract: CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma
